Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis Wins $2M SBIR Grant From NCI

NEW YORK – Single-cell proteomics firm IsoPlexis said today it has received a $2 million grant from the National Cancer Institute's Small Business Innovation Research (SBIR) Development Center.

The grant will fund development of methods using the company's IsoLight system to study protein signaling pathways in single tumor cells, allowing for improved analysis of cancer signaling and tumor heterogeneity.

Isoplexis's platform uses microchips featuring arrays of thousands of microchambers that isolate individual cells from samples of interest. These chambers are then sealed with a slide that is patterned with groups of antibodies in a number of different spatially isolated lines. This allows the researchers to identify proteins based on the color of fluorescence produced upon binding and the location on the slide where the binding event occurs. In this way, they can multiplex well beyond the levels allowed by fluorescence readout alone.

The award follows a $4 million SBIR grant the company received earlier this year as well as a $1.8 million SBIR grant it received in 2017.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.